Company Quick10K Filing
Immune Pharmaceuticals
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 45 $4
S-1 2018-11-21 Public Filing
10-Q 2018-11-14 Quarter: 2018-09-30
10-Q 2018-08-14 Quarter: 2018-06-30
10-Q 2018-05-15 Quarter: 2018-03-31
10-K 2018-04-02 Annual: 2017-12-31
10-Q 2017-11-14 Quarter: 2017-09-30
10-Q 2017-08-21 Quarter: 2017-06-30
10-Q 2017-06-14 Quarter: 2017-03-31
10-K 2017-05-17 Annual: 2016-12-31
10-Q 2016-11-18 Quarter: 2016-09-30
10-Q 2016-08-15 Quarter: 2016-06-30
10-Q 2016-05-16 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
10-Q 2015-11-16 Quarter: 2015-09-30
10-Q 2015-08-14 Quarter: 2015-06-30
10-Q 2015-05-15 Quarter: 2015-03-31
10-K 2015-04-15 Annual: 2014-12-31
10-Q 2014-11-17 Quarter: 2014-09-30
10-Q 2014-08-14 Quarter: 2014-06-30
10-Q 2014-05-20 Quarter: 2014-03-31
10-K 2014-04-09 Annual: 2013-12-31
10-Q 2013-11-19 Quarter: 2013-09-30
10-Q 2013-08-02 Quarter: 2013-06-30
10-Q 2013-05-20 Quarter: 2013-03-31
10-K 2013-03-05 Annual: 2012-12-31
10-Q 2012-08-10 Quarter: 2012-06-30
10-Q 2012-05-10 Quarter: 2012-03-31
10-K 2012-03-30 Annual: 2011-12-31
10-Q 2011-11-10 Quarter: 2011-09-30
10-Q 2011-08-15 Quarter: 2011-06-30
10-Q 2011-05-10 Quarter: 2011-03-31
10-K 2011-03-31 Annual: 2010-12-31
10-Q 2010-11-09 Quarter: 2010-09-30
10-Q 2010-08-06 Quarter: 2010-06-30
10-Q 2010-05-07 Quarter: 2010-03-31
10-K 2010-03-15 Annual: 2009-12-31
8-K 2019-02-17 Bankruptcy, Officers, Exhibits
8-K 2019-02-08 Off-BS Arrangement, Exhibits
8-K 2018-12-19 Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-12-05 Other Events, Exhibits
8-K 2018-11-26 Off-BS Arrangement
8-K 2018-11-23 Other Events, Exhibits
8-K 2018-10-18
8-K 2018-10-09 Other Events, Exhibits
8-K 2018-09-12 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-09-10 Officers
8-K 2018-08-28 Officers, Exhibits
8-K 2018-07-24 Regulation FD, Exhibits
8-K 2018-06-04 Regulation FD, Exhibits
8-K 2018-05-14 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-05-01 Officers, Other Events, Regulation FD, Exhibits
8-K 2018-02-23 Shareholder Vote, Regulation FD, Exhibits
8-K 2018-02-15 Shareholder Vote, Regulation FD, Exhibits
8-K 2018-02-12 Regulation FD, Exhibits
8-K 2018-02-07 Other Events, Exhibits
8-K 2018-01-25 Other Events, Exhibits
8-K 2018-01-09 Regulation FD, Exhibits

Immune Pharmaceuticals Financials

IMNP Metrics, Comps, Filings

Annual | Quarterly

Business

Immune Pharmaceuticals Inc., together with its subsidiaries (collectively, “Immune” or the “Company” or “us,” “we,” or “our”) is a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology.

Our lead product candidate is bertilimumab, a first-in-class, fully human, anti-eotaxin-1 antibody, currently in phase 2 clinical trials for bullous pemphigoud (“BP”) and ulcerative colitis (“UC”). Also, we are developing “NanoCyclo,” a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (“AD”) and psoriasis.

Our pain portfolio includes AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia (“PHN”) and diabetic peripheral neuropathy (“DPN”). We are determining the optimal path forward for this program.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Patriot Gold (PGOL) 3,714 0% 1,706 233 0 0 0 0 3,601
Encision (ECIA) 3,699 52% -777.5 -4% 4,345 2,168 8,327 4,371 -182 -5 3,563
Innovus Pharmaceuticals (INNV) 3,698 -127% -0.9 -77% 10,837 10,791 2,754 -3,502 -8,358 -6,105 5,258
Blake Insomnia Therapeutics (BKIT) 3,681 -90.8 0 237 0 0 -41 -41 3,681
Geospatial (GSPH) 3,659 71% -5.1 -904% 116 3,479 569 404 -1,052 -713 3,629
Visium Technologies (VISM) 3,647 -2.1 -9,417% 19 3,263 0 0 -1,758 -1,758 3,628
Cartesian (CRTN) 3,632 30% -0.4 -44% 16,522 17,461 47,555 14,053 -7,270 -5,582 2,087
GraniteShares Platinum Trust (PLTM) 3,632 -27.7 -4% 3,656 1 0 0 -131 -131 3,632
Invesco CurrencyShares Singapore Dollar Trust (FXSG) 3,628 0% -60.3 1% 3,637 1 36 0 21 21 -1,288
Fieldpoint Petroleum (FPP) 3,628 0% -1.3 -73% 4,528 6,259 2,144 0 -3,322 -2,684 3,414
American Church Mortgage (ACMC) 3,607 1.9 -0% 39,356 28,807 0 0 -26 1,891 3,607
Immune Pharmaceuticals (IMNP) 3,597 -0.9 -71% 20,716 19,874 0 0 -14,715 -13,953 12,494
American Bio Medica (ABMC) 3,580 30% -8.9 -42% 2,165 2,584 3,643 1,091 -911 -556 4,972
Empire Petroleum (EMPR) 3,576 0% -3.1 -27% 11,766 12,693 2,753 0 -3,134 -3,263 10,156
Genesis Financial (GFNL) 3,571 0% -1.1 -155% 2,427 3,394 10 0 -3,756 -3,242 3,551
Frontier Oilfield Services (FOSI) 3,542 0% 11.0 1% 3,685 11,058 737 0 35 1,043 11,475
Sauer Energy (SENY) 3,496 49% -2.8 -116% 1,092 291 30 15 -1,271 -1,239 3,494
PowerVerde (PWVI) 3,493 0% -8.5 -337% 131 322 31 0 -442 -428 3,655
Puradyn Filter Technologies (PFTI) 3,451 37% -24.8 -33% 2,797 12,529 3,117 1,150 -917 -503 12,470
Invesco CurrencyShares Chinese Renminbi Trust (FXCH) 3,420 0% 1,336.0 -0% 3,556 1 5 0 -16 -16 -21,016

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-09-30
Cash6,378172496,7674,5432716,77676
Accounts Receivable
Inventory57
PP&E120567341371316097
Assets7,5211,32831,50137,86436,18419,10528,60820,716
Accounts Payable1,1231,3495,1811,2432,4393,5223,5695,535
Long-Term Debt3764093873875,3878,300
Liabilities24,66715,29726,01820,32026,66216,59214,85019,874
Stockholders' Equity-17,146-13,9695,48317,5447,8632,51313,758842
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-09-30
Revenue9447,804192000
Cost of Revenue
Gross Profit
R&D7,8533,4003,5715,6405,9358,3335,517
SG&A6,4524,6075,44810,7259,7896,4276,606
Tax4270081-1,973
Net Income-2,573-5,760-23,550-17,157-32,661-17,889
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-09-30
Cash Operating-14,002-5,339-3,868-13,864-13,906-12,307-11,559
Cash Investing97-839-1,132117-177-5031
Cash Financing17,840-134,95420,46511,8598,08518,033